Amneal Pharmaceuticals, Inc. Financials

Market Capitalization $3.92 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	89.83
Forward PE	11.86
Price to Sales TTM	$1.39
Price to Book MRQ	$-44.10
Enterprise to Revenue	1.81
Enterprise to EBITDA	8.47

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-0.46%
Operating Margin	14.51%
Return on Assets TTM	6.67%
Return on Equity TTM	106.73%

Income Statement

Revenue TTM	$2,830,185,984
Revenue per Share TTM	$9.13
Quarterly Revenue Growth	5.50%
Gross Profit TTM	$1,032,561,024
EBITDA	$612,228,000
Net Income to Common TTM	$-13,048,000
Diluted EPS TTM	$-0.04
Quarterly Earnings Growth YoY	5.50%

Balance Sheet

Total Cash MRQ	$61,625,000
Total Cash per Share MRQ	$0.20
Total Debt MRQ	$
Total Debt to Equity MRQ	-43.43
Current Ratio MRQ	1.40
Book Value per Share MRQ	$-0.42

Cash Flow

Operating Cash Flow TTM	$306,916,992
Levered Free Cash Flow TTM	$311,479,360

AMRX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	309,881,000
Float Shares	167,181,148
Avg 10 Volume	1,957,810
Avg 30 Volume	None
Shares Short	5,354,663
Short Ratio	3.37
Short % of Shares	2.66%
% Held by Insiders	46.75%
% Held by Institutions	44.24%

Stock Price Summary

Beta	1.06
Fifty Two Week Low	$6.50
Fifty Two Week High	$9.48
Fifty Two Week Change	20.78%
Day 50 MA	$7.64
Day 200 MA	$8.12

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date